KR900701256A - 생물학적 활성을 가진 분자 수송에 유용한 미립자 벡터(vector) 및 미립자 벡터의 제조 과정 - Google Patents

생물학적 활성을 가진 분자 수송에 유용한 미립자 벡터(vector) 및 미립자 벡터의 제조 과정

Info

Publication number
KR900701256A
KR900701256A KR1019900700145A KR900700145A KR900701256A KR 900701256 A KR900701256 A KR 900701256A KR 1019900700145 A KR1019900700145 A KR 1019900700145A KR 900700145 A KR900700145 A KR 900700145A KR 900701256 A KR900701256 A KR 900701256A
Authority
KR
South Korea
Prior art keywords
carrier
core
layer
carrier according
particulate
Prior art date
Application number
KR1019900700145A
Other languages
English (en)
Other versions
KR0124414B1 (ko
Inventor
사마인 다니엘
벡 쟌루이스
코엔 에디스
뉴엔 프레드릭
페이로 마리안느
Original Assignee
원본미기재
상뜨르 나쇼날 드라 레쉐르쉐 상띠픽(Cnrs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 상뜨르 나쇼날 드라 레쉐르쉐 상띠픽(Cnrs) filed Critical 원본미기재
Publication of KR900701256A publication Critical patent/KR900701256A/ko
Application granted granted Critical
Publication of KR0124414B1 publication Critical patent/KR0124414B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/783—Organic host/matrix, e.g. lipid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/805—Containing drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/806—Virus-based particle with exterior chemical attachment
    • Y10S977/808—Exterior attachment for targeting, e.g. drug targeting
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/827—Nanostructure formed from hybrid organic/inorganic semiconductor compositions
    • Y10S977/829—Organic or biological core coated with inorganic shell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Abstract

내용 없음

Description

생물학적 활성을 가진 분자 수송에 유용한 미립자 벡터(vector) 및 미립자 벡터의 제조과정
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (27)

  1. 미립자 담체에 있어서, 친수성인 비유동체 코어: 공유결합에 의해 결합된 지질류의 제1층 또는 환: 소수성 상호작용에 의해 제1지질충에 결합된 양친매성 화합물의 제2층 또는 외부 껍질을 포함함을 특징으로 하는 미립자 담체.
  2. 제1항에 있어서, 상기 친수성 코어는 다리결합된 친수성 중합체로 구성됨을 특징으로 하는 담체.
  3. 제2항에 있어서, 상기 다리결합된 친수성 중함체는 다리결합된 다당류 임을 특징으로 하는 담체.
  4. 제3항에 있어서, 상기 다당류는 덱스트란, 녹말 및 셀룰로오스 및 상기 다당류 유도체에서 선택된 것임을 특징으로 하는 담체.
  5. 제3항 및 4항중 어느 하나에 있어서, 상기 다당류 유도체가 코어 용량 내에 균일하게 분포된 산성 또는 염기성인 이온 전하는 운반함을 특징으로 하는 담체.
  6. 제5항에 있어서, 상기 다당류 유도체가 다당류의 OH기(sic)를 가지고 공유 결합시킬 수 있는 화합물과의 반응으로 생성되고 또한 양성 또는 음성의 이온기를 운반함을 특징으로 하는 담체.
  7. 제5항 및 6항중 어느 하나에 있어서, 상기 화합물이 숙신산 또는 숙신산 유도체임을 특징으로 하는 담체.
  8. 제1항 내지 7항중 어느 하나에 있어서, 코어의 평균 크기는 10nm 내지 5nm임을 특징으로 하는 담채,
  9. 제8항에 있어서, 코어의 평균 크기는 20nm 내지 70㎛임을 특징으로 하는 담체.
  10. 제1항 내지 9항중 어느 하나에 있어서, 제1층은 스테롤, 지방산, 지방아민, 인지질, 소수성 아미노산 및 알콜시 에테르 및 상기 물질의 혼합물에서 선택되어진 화합물로 구성됨을 특징으로 하는 방법.
  11. 제1항 내지 제10항중 어느 하나에 있어서, 지질층은 히드록시기 또는 상기 코어의 히드록시기에서 유도된 작용기에 의해 코어에 화학적으로 연결됨을 특징으로 하는 담체.
  12. 제1항 내지 11항중 어느 하나에 있어서, 제2층은 인지질 또는 계면 활성제로 구성됨을 특징으로 하는 담체.
  13. 제1항 내지 12항중 어느 하나에 있어서, 어느 한 층 또는 코어에 생물학적 활성을 가진 분자가 포함됨을 특징으로 하는 담체.
  14. 제1항 내지 13항중 어느 하나에 있어서, 상기 생물학적 활성을 가진 분자는 항생물질 및 항비루스제; 단백질, 프로테오글리칸(sic) 밌 펩티드: 다당류 및 지다당류: 항체: 살충제 및 살균제: 심혈관계에 작용하는 화합물: 항암제: 항 말라리아제 및: 항천식제에서 선택된 것임을 특징으로 하는 담체.
  15. 제1항 내지 14항중 어느 하나에 있어서, 담체가 표지됨을 특징으로 하는 담체.
  16. 제15항에 있어서, 상기 담체가 방사선으로 표지됨을 특징으로 하는 담체.
  17. 제1항 내지 16항중 어느 하나에 있어서, 상기 담체는 살균됨을 특징으로 하는 담체.
  18. 제1항 내지 17항중 어느 하나에 있어서, 상기 담체는 냉동 건조 형태 또는 냉동건조제가 분무된 형태로 존재함을 특징으로 하는 담체.
  19. 제18항에 있어서, 냉동 건조제가 당(sugar)임을 특징으로 하는 담체.
  20. 제1항 내지 19항중 어느 하나에 있어서, (가) 코어는 10nm 내지 5㎛ 범위의 입자를 얻을 수 있는 조건하에서 친수성 중합체로 다리결합시켜 제조하고, (나) 지질 화합물은 제1층 형성을 위해 코어 표면에서 반응기를 화학적으로 연결시키고, (다) 최종적으로 양친매성 화합물은 제2층 생성을 위해 제1층에 소수성 접촉제를 도입함을 특징으로 하는 미립자 담체의 제조과정.
  21. 제20항에 있어서. (가) 단계에서 입자는 발효에 의해 생성됨을 특징으로 하는 과정.
  22. 제20항 내지 21항에 있어서, 다당류에 대한 비용제인 비양성자성 매질에서 (나)단계는 실시됨을 특징으로 하는 과정
  23. 제20항 내지 22항중 어느 하나에 있어서, (다)단계는 리포좀 제조방법에 따라 처리됨을 특징으로 하는 과정.
  24. 제20항 내지 23항중 어느 하나에 있어서, 생물학적 활성을 가지는 분자가 상기 과정중 어느 한 단계가 일어나는 동안 또는 최종 담체내로 도입됨을 특징으로 하는 과정.
  25. 제1항 내지 19항중 어느 하나에 있어서, 담체를 포함함을 특징으로 하는 생물학적 활성을 가진 조성물.
  26. 제13항 내지 14항중 어느 하나에 따른 미립자 담체가 활성제로 포함됨을 특징으로 하는 약제학적 조성몰.
  27. 진단제로 사용되는 제15항 및 16항중 어느 하나에 따른 미립자 운반체.
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700145A 1988-05-27 1989-05-11 생물학적 활성을 가진 분자의 수송에 유용한 입자성 담체 및 이의 제조방법 KR0124414B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8807110 1988-05-27
FR8807110A FR2631826B1 (fr) 1988-05-27 1988-05-27 Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
PCT/FR1989/000229 WO1989011271A1 (fr) 1988-05-27 1989-05-11 Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation

Publications (2)

Publication Number Publication Date
KR900701256A true KR900701256A (ko) 1990-12-01
KR0124414B1 KR0124414B1 (ko) 1997-11-25

Family

ID=9366698

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700145A KR0124414B1 (ko) 1988-05-27 1989-05-11 생물학적 활성을 가진 분자의 수송에 유용한 입자성 담체 및 이의 제조방법

Country Status (11)

Country Link
US (1) US5151264A (ko)
EP (1) EP0344040B1 (ko)
JP (1) JP2864033B2 (ko)
KR (1) KR0124414B1 (ko)
AT (1) ATE77741T1 (ko)
CA (1) CA1341259C (ko)
DE (1) DE68901955T2 (ko)
ES (1) ES2054048T3 (ko)
FR (1) FR2631826B1 (ko)
GR (1) GR3005670T3 (ko)
WO (1) WO1989011271A1 (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646777B1 (fr) * 1989-05-12 1993-09-03 Bio Serae Lab Procede de preparation d'un produit particulaire antimicrobien, produit antimicrobien obtenu et applications
US5736371A (en) * 1991-06-04 1998-04-07 A Et S Biovecteurs Biodegradable particulate vector for transporting molecules having biological activity
US5534501A (en) * 1991-06-04 1996-07-09 A Et S Biovecteurs Particle for use as a milk fat globule substitute, composition containing same and process for the preparation of said particle
FR2677249B1 (fr) * 1991-06-04 1995-03-17 Biovecteurs As Vecteur particulaire biodegradable et procede de synthese.
FR2677272B1 (fr) * 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
FR2677897B1 (fr) * 1991-06-24 1993-10-01 Oreal Procede de preparation de particules submicroniques en presence de vesicules lipidiques et compositions correspondantes.
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) * 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5534259A (en) * 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
FR2723849B1 (fr) * 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5635487A (en) * 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
US5498705A (en) * 1995-02-22 1996-03-12 Kimberly-Clark Corporation Modified polysaccharides having improved absorbent properties and process for the preparation thereof
FR2742357B1 (fr) * 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US5776490A (en) * 1996-01-26 1998-07-07 The Center For Innovative Technology Complex protein-walled microcapsules containing lipid-walled microcapsules and method for producing same
US6344202B1 (en) * 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
FR2753902B1 (fr) * 1996-09-27 1999-04-02 Ioualalen Karim Nouveau type de matrice ionique biodegradable de polarite interne modulable a polymere greffe
FR2754828B1 (fr) * 1996-10-23 1998-12-24 Univ Toulouse Structure membranaire artificielle, procede et polymere pour sa preparation, procede de preparation de ce polymere, particule et film comprenant cette structure
FR2757876B1 (fr) * 1996-12-27 1999-04-09 Biovector Therapeutics Sa Conjuges d'un vecteur particulaire et d'oligonucleotides, leur procede de preparation et les compositions pharmaceutiques les contenant
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US6319507B1 (en) 1997-05-02 2001-11-20 Kobo Products, Inc. Agar gel bead composition and method
US5961990A (en) * 1997-05-02 1999-10-05 Kobo Products S.A.R.L. Cosmetic particulate gel delivery system and method of preparing complex gel particles
KR100554608B1 (ko) 1998-04-24 2006-02-24 바스프 코포레이션 개선된 압출 방법
MX220923B (es) * 1999-01-25 2004-06-11 Ato Bv Nanoparticulas biopolimericas.
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
US6811783B1 (en) * 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US20030108585A1 (en) * 2001-05-04 2003-06-12 Roe R. Michael Polymer conjugates of insecticidal peptides or nucleic acids or insecticides and methods of use thereof
US20020187178A1 (en) * 2001-05-04 2002-12-12 Roe R. Michael Polymer conjugates of insecticidal peptides or nucleic acids and methods of use thereof
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
JP2006525333A (ja) * 2003-05-02 2006-11-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 高親水性で正電荷に帯電した薬剤を取り込んだ生分解性ナノ粒子
US6809197B1 (en) 2003-06-11 2004-10-26 Mgp Ingredients, Inc. Emulsion stabilizing starch products
US7166305B2 (en) * 2003-06-11 2007-01-23 Mgp Ingredients, Inc. Polyvalent metal-substituted starch products
WO2005027873A2 (en) * 2003-06-20 2005-03-31 Alnis Biosciences, Inc. Therapeutic aminoglycoside-containing hydrogel nanoparticles
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
DE102005037844A1 (de) * 2005-08-04 2007-04-05 Intendis Gmbh Wasserfreies Mehr-Phasen-Gel-System
US8865197B2 (en) * 2005-09-06 2014-10-21 Israel Oceanographic And Limnological Research Ltd. Food formulation for aquatic animals with integrated targeted delivery of bioactive agents
JP2010511415A (ja) * 2005-12-01 2010-04-15 イノグラフト，リミティド ライアビリティー カンパニー 薄皮膜の施用のためにポリサッカライド物質をイオン架橋する方法及びそれから生成された製品
KR100792557B1 (ko) * 2006-04-05 2008-01-09 한남대학교 산학협력단 나노 캡슐화를 이용하여 제조된 지질 핵 및 고분자 쉘구조를 갖는 단백질 약물 전달용 나노 미립구
US8920808B2 (en) 2006-10-31 2014-12-30 East Carolina University Cytokine-based fusion proteins for treatment of multiple sclerosis
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
AU2010234743A1 (en) 2009-03-31 2011-10-20 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
US9801954B2 (en) 2013-11-05 2017-10-31 Arizona Board Of Regents On Behalf Of Arizona State University Lipid substitution on aminoglycoside based polymers: plasmid delivery, anticancer drug delivery and transgene expression
WO2016130928A1 (en) 2015-02-12 2016-08-18 Arizona Board Of Regents On Behalf Of Arizona State University Aminoglycoside hydrogel microbeads and macroporous gels with chemical crosslink, method of preparation and use thereof
EP3355910A4 (en) 2015-09-28 2019-08-28 East Carolina University ALUMINUM-BASED ADJUVANTS FOR TOLEROGENIC VACCINATION
CN116063687B (zh) * 2021-11-01 2024-05-07 中国石油化工股份有限公司 一种疏水石英砂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3242051A (en) * 1958-12-22 1966-03-22 Ncr Co Coating by phase separation
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
FR2596399B1 (fr) * 1986-03-28 1988-09-02 Univ Rennes Nanoparticules a base de polymere ou copolymere methacrylique, procede de preparation, et application comme vecteur de medicament

Also Published As

Publication number Publication date
FR2631826A1 (fr) 1989-12-01
ATE77741T1 (de) 1992-07-15
KR0124414B1 (ko) 1997-11-25
ES2054048T3 (es) 1994-08-01
WO1989011271A1 (fr) 1989-11-30
EP0344040B1 (fr) 1992-07-01
US5151264A (en) 1992-09-29
DE68901955T2 (de) 1993-02-04
CA1341259C (fr) 2001-06-19
GR3005670T3 (ko) 1993-06-07
JPH04500662A (ja) 1992-02-06
JP2864033B2 (ja) 1999-03-03
EP0344040A1 (fr) 1989-11-29
FR2631826B1 (fr) 1992-06-19
DE68901955D1 (de) 1992-08-06

Similar Documents

Publication Publication Date Title
KR900701256A (ko) 생물학적 활성을 가진 분자 수송에 유용한 미립자 벡터(vector) 및 미립자 벡터의 제조 과정
US5198493A (en) Method of covalently bonding biopolymer to a solid hydrophilic organic polymer
FI90628B (fi) Kudossiirrännäisen käsittelymenetelmä
US5405766A (en) Immobilization of biologically active protein on a support with a 7-18 carbon spacer and a bifunctional phospholipid
US4478914A (en) Process for applying multiple layers of a protein and a ligand extender to a surface and to the multiple-layer system
Porath et al. [3] Immobilization of enzymes to agar, agarose, and sephadex support
US4282287A (en) Biochemical avidin-biotin multiple-layer system
EP0484472B1 (de) Verfahren zur lichtinduzierten immobilisierung von biomolekülen an chemisch "inerten" oberflächen
Pidgeon et al. Preparation of mixed ligand immobilized artificial membranes for predicting drug binding to membranes
JP2003517998A (ja) ナノカプセル及びその製造方法
USRE31712E (en) Biochemical avidin-biotin multiple-layer system
JPH08509246A (ja) エステル化した多糖類とポリアミン化またはポリヒドロキシル化した物質の間のトランスアシル化反応の微粒子製造への使用、そのようにして製造された微粒子、方法、およびそれを含有する組成物
JPH06502156A (ja) 共有結合された生体高分子を含む親水性の外層によって被覆された固体表面、そのような表面を製造する方法、およびそのための共役体
JPH026750A (ja) 生物試料分離用のカラム充填材若しくはクロマトグラフィー部材として用いるアガロースコーティングガラス繊維
Kim et al. Immobilization methods for affinity chromatography
Spiegel et al. Membrane sialoglycolipids emerging as possible signal transducers for lymphocyte stimulation.
Torchilin et al. Immobilization of proteins on liposome surface
KR930701158A (ko) 생분해성 미립자 벡터 및 그의 합성 방법
AU1426300A (en) Squaric acid activated carrier usable for immobilisation of compounds containingamine groups
JPS62212568A (ja) 糖鎖特異抗体アツセイプレ−ト及びその製造方法
JP3509142B2 (ja) 反応性リポソームおよび形成剤
Yamakawa Glycolipids of mammalian red blood cells
EP0506818B1 (en) Method of covalently bonding proteins to hydrophilic surfaces
JP3428044B2 (ja) 反応性リポソームおよび形成剤
JP3207878B2 (ja) 生体物質の固相化方法

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
N231 Notification of change of applicant
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

Free format text: TRIAL NUMBER: 1997201001004; APPEAL AGAINST DECISION TO DECLINE REFUSAL

B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060925

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee